Pharmacological Effects of “Jutsu” (Atractylodis rhizome and Atractylodis lanceae rhizome) on 1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-Induced Head Twitch Response in Mice (I)

Hallucinations are a common non-motor symptom of Parkinson’s disease and various forms of dementias. Yokukansan and Yokukansankachimpihange have attracted attention due to their effectiveness in the treatment of hallucinations of dementia. To clarify which component in these formulas contribute to the effects, at first, we focused on their differences in compositions to examine the pharmacological effects on the selective 5-HT2A/2C agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced head-twitch response (HTR) in mice that has been used as animal hallucination model. Results indicated that water extract of Byaku-jutsu (Atractylodes japonica) showed a stronger inhibitory effect on DOI-induced HTR than that of So-jutsu (A. lancea) corresponding to their major constituents of atractylenolide III and β-eudesmol, and suggested that the major constituents should be active constituents contributing to the antihallucination effects of Byaku- and So-jutsu. Besides, the part B–C ring (butenolide) in atractylenolide III was found to be similar to the structure of serotonin and suggested that the B–C ring may partially play role in antagonistic activity against serotonin receptors. Thus, a novel, rational design of butenolide-related compounds may as potential lead compounds for new drug development. Analysis of the chemical components of Byaku- and So-jutsu and further study on their structure-activity relationships are currently in progress.

[1]  John-Paul Taylor,et al.  Visual Hallucinations in PD and Lewy Body Dementias: Old and New Hypotheses , 2013, Behavioural neurology.

[2]  S. Yamaguchi,et al.  Improvement in delusions and hallucinations in patients with dementia with Lewy bodies upon administration of yokukansan, a traditional Japanese medicine , 2012, Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society.

[3]  D. E. Nichols,et al.  Structure–activity relationships of serotonin 5‐HT2A agonists , 2012 .

[4]  N. Hattori,et al.  Successful treatment with Yokukansan for behavioral and psychological symptoms of Parkinsonian dementia , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[5]  Yan Hua-zhong.  Effects of biatractylolide on the AD rats induced by Aβ_(1-40) , 2009 .

[6]  Ayumi Ishibashi,et al.  Repeated administration of Yokukansan inhibits DOI-induced head-twitch response and decreases expression of 5-hydroxytryptamine (5-HT)2A receptors in the prefrontal cortex , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[7]  Ling-Ling Yang,et al.  Analysis of the sesquiterpenoids in processed Atractylodis Rhizoma. , 2007, Chemical & pharmaceutical bulletin.

[8]  Oka Hiroaki,et al.  031 Clinical Trials with Allogeneic Cultured Dermal Substitutes for the Treatment of Burns and Skin Ulcers (Regenerating Medical Millennium Project of the Ministry of Health, Labor and Welfare) , 2004 .

[9]  S. Corne,et al.  A possible correlation between drug-induced hallucinations in man and a behavioural response in mice , 2004, Psychopharmacologia.

[10]  A C Moffat,et al.  Drugs of abuse. , 2000, Science & justice : journal of the Forensic Science Society.

[11]  Trevor Sharp,et al.  A review of central 5-HT receptors and their function , 1999, Neuropharmacology.

[12]  Simon Wills,et al.  Drugs of Abuse , 1997 .

[13]  N. Darmani,et al.  Differential Ontogenesis of Three DOI-Induced Behaviors in Mice , 1996, Physiology and Behavior.

[14]  I. Yosioka,et al.  STUDIES ON THE CONSTITUENTS OF ATRACTYLODES. IX. STRUCTURE AND AUTOXIDATION OF ATRACTYLON. , 1964, Chemical & pharmaceutical bulletin.

[15]  I. Yosioka,et al.  Structure and autoxidation of atractylon. , 1962, Chemical & pharmaceutical bulletin.

[16]  I. Yosioka,et al.  Studies on the Constituents of Atractylodes. IV. The Structure of Hinesol. (1). The Skeleton , 1959 .